SDI.ASX RZI.ASX NEU.ASX 8CO.ASX VBC.ASX

SDI Enters into a Scheme Implementation Deed

SDI Limited (ASX:SDI) has entered into a Scheme Implementation Deed with Beijing Guoci Kebo Technology Co., Ltd, a subsidiary of Shandong Sinocera Functional Material Co. Ltd, to acquire 100% of SDI's issued share capital for A$1.40 per share in cash. This represents a 65% premium to the pre-announcement share price and a 56% premium to SDI's 30-day volume weighted average price.

The SDI Board unanimously recommends the Scheme, and the company's largest shareholder has confirmed its intention to vote in favor. This acquisition will unite SDI's innovation capabilities, trusted brand portfolio, and deep relationships with Sinocera's leading functional materials expertise, manufacturing scale, and investment capacity, creating a stronger, more globally competitive platform in advanced dental materials.

Raiz Invest Reports Strong Revenue Growth, Improved Profitability

Raiz Invest Limited (ASX:RZI) has reported impressive financial results for the half-year ended 31 December 2025. The company generated revenue of $14.4 million, up 23.9%, driven by a 5.7% increase in Active Customers to 336,048 and a 16.4% increase in ARPU to $86.45. Underlying EBITDA surged 270% to $2.6 million, and Raiz delivered NPAT of $3.52 million, which includes an income tax benefit.

Funds Under Management increased by 28.5% to $2.1 billion, and the company has reaffirmed its FY26 Earnings Guidance, with UEBITDA expected to be in the range of $4.5 million to $5.5 million. Raiz is focused on maximizing value across the customer lifecycle through innovative products and expanding its capabilities to introduce new transaction-based revenue streams.

2025 royalty income A$65m, profit after tax A$30m

Neuren Pharmaceuticals Limited (ASX: NEU) reported strong financial results for 2025, with royalty income from DAYBUE® (trofinetide) of A$65 million, up 15% from 2024, and a profit after tax of A$30 million. The company also announced the commencement of its Koala Phase 3 clinical trial for NNZ-2591 in Phelan-McDermid syndrome.

Acadia Pharmaceuticals, Neuren's exclusive worldwide licensee for trofinetide, provided guidance for 2026 DAYBUE net sales of US$460-490 million, implying royalties to Neuren of A$70-77 million. Neuren's strong cash position of A$296 million supports the ongoing development programs and a new A$50 million on-market share buy-back.

SDI Ltd Reports Half-Year Results

SDI Ltd reported a 15.2% decrease in net profit after tax to $3.25 million for the half-year ended 31 December 2025. Total sales increased by 2.7% to $52.9 million, but this was offset by the continual decline in Amalgam product sales. Product margins improved to 65.6%, up 210 bps, reflecting operational efficiencies, geographical and product mix, and favorable currency movements.

The company remains focused on its strategic priorities, including the development of Aesthetics and Whitening products, achieving manufacturing and logistic efficiencies, and investment in production automation and research and development.

8COMMON Ltd Reports Half Yearly Results

8COMMON Ltd reported a 14% decrease in revenue and other income to $3.23 million for the half-year ended 31 December 2025. However, the company achieved an EBITDA profit of $248,000, a significant improvement from the $318,000 loss in the prior period, driven by decreases in cost of services and operational expenses.

The company anticipates that as more federal government and large enterprise entities progress to the on-boarding phase of Expense8, user numbers will continue to grow in coming quarters, driving a increase in ARPU and delivering material revenue growth. 8COMMON continues to expand its presence amongst government, not-for-profit, and large enterprise clients.

Verbrec Provides FY2026 Revenue & Earnings Guidance

Verbrec Limited (ASX: VBC) has provided revenue and earnings guidance for the full year ending 30 June 2026. The company expects continuing operations revenues of $110 million to $120 million, an increase of at least 41% year-on-year, and continuing operations EBITDA of $8 million to $10 million. Total group EBITDA is expected to be $15.3 million to $17.3 million.

Verbrec Reports Strong H1 FY2026 Results

Verbrec Ltd (ASX:VBC) has announced strong H1 FY2026 results, with EBITDA of $11.3 million and a net cash position of $11.6 million. The acquisition of Alliance Automation is complete and expected to contribute over $60 million in annual revenue, while the company's opportunity pipeline and work-in-hand have increased significantly.

Verbrec is positioned for growth driven by organic opportunities and synergies from the Alliance Automation acquisition. The company's net cash position and bolstered opportunity pipeline provide the opportunity to pursue further strategic acquisitions and growth initiatives.